CAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products

Biochemical Journal

Volumn 463, Issue 1, 2014, Pages 75-82

  Motoyoshi, So ^a   Yamamoto, Yasuhiko ^a   Munesue, Seiichi ^a   Igawa, Hirobumi ^a   Harashima, Ai ^a   Saito, Hidehito ^a   Han, Dong ^a   Watanabe, Takuo ^a   Sato, Hiroshi ^a   Yamamoto, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

CAMP; Decoy receptor; Macrophage; Receptor for advanced glycation end products (RAGE); Shedding

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN S100B; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CCL2 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; MMP9 PROTEIN, MOUSE; S100B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COS 7 CELL LINE; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA CELL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PERITONEAL FLUID; PERITONEUM MACROPHAGE; PERITONITIS; PROTEIN EXPRESSION; TISSUE INJURY; UPREGULATION; ANIMAL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; CHEMOKINE CCL2; CYCLIC AMP; INFLAMMATION; MACROPHAGES, PERITONEAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECEPTORS, IMMUNOLOGIC; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SIGNAL TRANSDUCTION;

EID: 84906972238     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140084     Document Type: Article

References (46)

1. Takeuchi, O. and Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805-820 CrossRef PubMed.
2. Rosin, D. L. and Okusa, M. D. (2011) Dangers within: DAMP responses to damage and cell death in kidney disease. J. Am. Soc. Nephrol. 3, 416-425 CrossRef.
3. Fujiwara, N. and Kobayashi, K. (2005) Macrophages in inflammation. Curr. Drug. Targets. Inflamm. Allergy. 3, 281-286 CrossRef.
4. Yamamoto, Y. and Yamamoto, H. (2013) RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Front. Endocrinol. 4, 105 CrossRef.
5. Ramasamy, R., Yan, S. F. and Schmidt, A. M. (2012) The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul. Pharmacol. 57, 160-167 CrossRef PubMed.
6. Leclerc, E., Fritz, G., Vetter, S. W. and Heizmann, C. W. (2009) Binding of S100 proteins to RAGE: An update. Biochim. Biophys. Acta 1793, 993-1007 CrossRef PubMed.
7. Yamamoto, Y., Harashima, A., Saito, H., Tsuneyama, K., Munesue, S., Motoyoshi, S., Han, D., Watanabe, T., Asano, M., Takasawa, S. et al. (2011) Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J. Immunol. 186, 3248-3257 CrossRef PubMed.
8. Tian, J., Avalos, A. M., Mao, S. Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C. et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 CrossRef PubMed.
9. Yamamoto, H., Watanabe, T., Yamamoto, Y., Yonekura, H., Munesue, S., Harashima, A., Ooe, K., Hossain, S., Saito, H. and Murakami, N. (2007) RAGE in diabetic nephropathy. Curr. Mol. Med. 7, 752-757 CrossRef PubMed.
10. Yan, S. F., Ramasamy, R. and Schmidt, A. M. (2008) Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 4, 285-293 CrossRef PubMed.
11. Myint, K. M., Yamamoto, Y., Doi, T., Kato, I., Harashima, A., Yonekura, H., Watanabe, T., Shinohara, H., Takeuchi, M., Tsuneyama, K. et al. (2006) RAGE control of diabetic nephropathy in a mouse model: Effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55, 2510-2522 CrossRef PubMed.
12. Rendon-Mitchell, B., Ochani, M., Li, J., Han, J., Wang, H., Yang, H., Susarla, S., Czura, C., Mitchell, R. A., Chen, G. et al. (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170, 3890-3897 CrossRef PubMed.
13. Harashima, A., Yamamoto, Y., Cheng, C., Tsuneyama, K., Myint, K. M., Takeuchi, A., Yoshimura, K., Li, H., Watanabe, T., Takasawa, S. et al. (2006) Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem. J. 396, 109-115 CrossRef PubMed.
14. Nishida, Y., Miyamori, H., Thompson, E. W., Takino, T., Endo, Y. and Sato, H. (2008) Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2. Cancer Res. 68, 9096-9104 CrossRef PubMed.
15. Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J. and Geczy, C. L. (2013) Functions of S100 proteins. Curr. Mol. Med. 13, 24-57 CrossRef PubMed.
16. Kolattukudy, P. E. and Niu, J. (2012) Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res. 110, 174-189 CrossRef PubMed.
17. Wall, E. A., Zavzavadjian, J. R., Chang, M. S., Randhawa, B., Zhu, X., Hsueh, R. C., Liu, J., Driver, A., Bao, X. R., Sternweis, P. C. et al. (2009) Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2, ra28 CrossRef PubMed.
18. Pierre, S., Eschenhagen, T., Geisslinger, G. and Scholich, K. (2009) Capturing adenylyl cyclases as potential drug targets. Nat. Rev. Drug. Discov. 8, 321-335 CrossRef PubMed.
19. Bender, A. T. and Beavo, J. A. (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharm. Rev. 58, 488-520 CrossRef.
20. Rovin, B. H., Dickerson, J. A., Tan, L. C. and Hebert, C. A. (1995) Activation of nuclear factor-kappa B correlates with MCP-1 expression by human mesangial cells. Kidney. Int. 48, 1263-1271 CrossRef PubMed.
21. Ueda, A., Ishigatsubo, Y., Okubo, T. and Yoshimura, T. (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J. Biol. Chem. 272, 31092-31099 CrossRef PubMed.
22. Grandoch, M., Roscioni, S. S. and Schmidt, M. (2010) The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br. J. Pharmacol. 159, 265-284 CrossRef PubMed.
23. Zhang, L., Bukulin, M., Kojro, E., Roth, A., Metz, V. V., Fahrenholz, F., Nawroth, P. P., Bierhaus, A. and Postina, R. (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 283, 35507-35516 CrossRef PubMed.
24. Raucci, A., Cugusi, S., Antonelli, A., Barabino, S. M., Monti, L., Bierhaus, A., Reiss, K., Saftig, P. and Bianchi, M. E. (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB. J. 22, 3716-3727 CrossRef PubMed.
25. Dinarello, C. A. (2010) Anti-inflammatory agents: Present and future. Cell 140, 935-950 CrossRef PubMed.
26. Metz, V. V., Kojro, E., Rat, D. and Postina, R. (2012) Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS ONE 7, e41823 CrossRef PubMed.
27. Billington, C. K. and Hall, I. P. (2012) Novel cAMP signalling paradigms: Therapeutic implications for airway disease. Br. J. Pharmacol. 166, 401-410 CrossRef PubMed.
28. Tan, K. C., Chow, W. S., Tso, A. W., Xu, A., Tse, H. F., Hoo, R. L., Betteridge, D. J. and Lam, K. S. (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50, 1819-1825 CrossRef PubMed.
29. Tam, H. L., Shiu, S. W., Wong, Y., Chow, W. S., Betteridge, D. J. and Tan, K. C. (2010) Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 209, 173-177 CrossRef PubMed.
30. Harris, R. (2005) Angiotensin-converting enzyme inhibition in diabetic nephropathy: it's all the RAGE. J. Am. Soc. Nephrol. 16, 2363-2372 CrossRef PubMed.
31. Pavlovic, S., Du, B., Sakamoto, K., Khan, K. M., Natarajan, C., Breyer, R. M., Dannenberg, A. J. and Falcone, D. J. (2006) Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J. Biol. Chem. 281, 3321-3328 CrossRef PubMed.
32. Yen, J. H., Khayrullina, T., Ganea, D., Yen, J. H., Khayrullina, T. and Ganea, D. (2008) PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111, 260-270 CrossRef PubMed.
33. Levine, S. J. (2004) Mechanisms of soluble cytokine receptor generation. J. Imuunol. 173, 5343-5348 CrossRef.
34. Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y. and Yamamoto, H. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275, 25781-25790 CrossRef PubMed.
35. Michaud, J., Im, D. S. and Hla, T. (2010) Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J. Immunol. 184, 475-1483 CrossRef.
36. Wendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S. et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137 CrossRef PubMed.
37. Suzuki, F., Kato, K. and Nakajima, T. (1983) Enhancement of adipose S-100 protein release by catecholamines. J. Biochem. 94, 1707-1710 PubMed.
38. Suzuki, F., Kato, K. and Nakajima, T. (1984) Hormonal regulation of adipose S-100 protein release. J. Neurochem. 43, 1336-1341 CrossRef PubMed.
39. Brozzi, F., Arcuri, C., Giambanco, I. and Donato, R. (2009) S100B Protein regulates astrocyte shape and migration via interaction with Src kinase: implication for astrocyte development, activation, and tumor growth. J. Biol. Chem. 284, 8797-8811 CrossRef PubMed.
40. Barile, G. R., Pachydaki, S. I., Tari, S. R., Lee, S. E., Donmoyer, C. M., Ma, W., Rong, L. L., Buciarelli, L. G., Wendt, T., Hörig, H. et al. (2005) The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 46, 2916-2924 CrossRef PubMed.
41. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C. et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835 CrossRef PubMed.
42. Yan, S. S., Wu, Z. Y., Zhang, H. P., Furtado, G., Chen, X., Yan, S. F., Schmidt, A. M., Brown, C., Stern, A., LaFaille, J. et al. (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 9, 287-293 CrossRef PubMed.
43. Fang, F., Lue, L. F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M. et al. (2009) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB. J. 23, 2639-2349 CrossRef PubMed.
44. Guo, J., Ananthakrishnan, R., Qu, W., Lu, Y., Reiniger, N., Zeng, S., Ma, W., Rosario, R., Yan, S. F., Ramasamy, R. et al. (2008) RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol. 19, 961-972 CrossRef PubMed.
45. Keshavarzian, A., Mutlu, E., Guzman, J. P., Forsyth, C. and Banan, A. (2007) Phosphodiesterase 4 inhibitors and inflammatory bowel disease: Emerging therapies in inflammatory bowel disease. Expert. Opin. Investig. Drugs. 16, 1489-1506 CrossRef PubMed.
46. Brown, W. M. (2007) Treating COPD with PDE 4 inhibitors. Int. J. Chron. Obstruct. Pulmon. Dis. 2, 517-533 PubMed.